TNFRSF11B and osteoporosis: PMOP is a classic orthopaedic disorder resulting from overactivated osteoclasts.7 The previous study demonstrated that oestrogen could exert anti‐osteoporosis effect by stimulating osteoblasts to secrete osteoprotegerin (OPG) and inhibiting osteoclastogenesis.8, 9 The oestrogen withdrawal after menopause leads to the overactivation of osteoclasts, which further leads to the increased bone turnover rate and net bone loss.7, 10